CN1171108A - 稳定性优良的8－烷氧基喹诺酮羧酸水合物及其制备方法 - Google Patents

稳定性优良的8－烷氧基喹诺酮羧酸水合物及其制备方法 Download PDF

Info

Publication number
CN1171108A
CN1171108A CN95196983A CN95196983A CN1171108A CN 1171108 A CN1171108 A CN 1171108A CN 95196983 A CN95196983 A CN 95196983A CN 95196983 A CN95196983 A CN 95196983A CN 1171108 A CN1171108 A CN 1171108A
Authority
CN
China
Prior art keywords
cyclopropyl
oxo
fluoro
piperazinyl
dihydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN95196983A
Other languages
English (en)
Other versions
CN1137890C (zh
Inventor
松本丰实
原正元
宫下国雄
加藤行広
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18290056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1171108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CN1171108A publication Critical patent/CN1171108A/zh
Application granted granted Critical
Publication of CN1137890C publication Critical patent/CN1137890C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

本发明提供稳定性优良的如下式(1)所示的1－环丙基－6－氟代－1,4－二羟基－8－甲氧基－7－(3－甲基－1－哌嗪基)－4－氧代－3－喹啉羧酸·3/2水合物及其制备方法。

Description

稳定性优良的8-烷氧基喹诺酮羧酸水合物及其制备方法
技术领域
本发明涉及稳定性优良的1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物及其制备方法。
技术背景
喹诺酮羧酸类抗菌剂近年来发展迅速，因具有从革兰氏阳性菌到革兰氏阴性菌的范围广泛的抗菌谱和很强的抗菌力，也可用于尿路感染以外的外科感染症，其有效性得到高度评价，在临床上作出重大贡献。
特别是1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸不仅因其优异的抗菌力，而且因其对细菌的选择性高及优异的选择毒性，而受到人们的注目。
特开昭62-252772号公报公开了式(2)所示的1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的半水合物。
1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-吡嗪基)-4-氧代-3-喹啉羧酸因吸湿性强而易于制成水合物，从含水有机溶剂中重结晶，将经酸-碱重结晶的中和结晶法所得的结晶干燥，很容易制成半水合物。
然而，人们发现，1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的半水合物随着湿度的升高而重量增加，而且在制片剂时崩解性和溶出性差，这样的制剂生产问题变得很明显。
发明的揭示
本发明者们以解决上述1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸半水合物的问题为目的进行研究，结果发现1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物是稳定的化合物，在制剂生产上效果也好。即，1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物在很宽的湿度条件下均稳定，而且片剂的崩解性和溶出性也良好。
而且，作为获得1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物的手段，本发明者发现，将1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的水悬浮液加热搅拌可高效地获得目的化合物，从而完成了本发明。
本说明书中的“水悬浮液”表示在精制阶段经酸-碱重结晶中和后的悬浮液、在分离所得的结晶中加水而成的悬浮液等，水的用量可按结晶的3-20倍加入，为使得到目的物的收率高，以用3-5倍为宜。
最好在50-100℃温度(以80-90℃为佳)搅拌10-30分钟。
水悬浮液的pH以中性附近(6.0-8.0)为佳。
此外，加热搅拌后滤取所得的目的物，将母液回至室温，可容易回收二次结晶，因此可使收率提高。
附图的简单说明
图1显示本发明物的热分析结果。
图2显示对照物的热分析结果。
图3显示本发明物的红外吸收谱。
图4显示对照物的红外吸收谱。
图5显示本发明物的X射线衍射结果。
图6显示对照物的X射线衍射结果。
图7显示本发明物的结晶结构。
实施发明的最佳方式
以下列出本发明的实施例，对本发明作更详细的说明，但本发明并不受这些实施例的任何限制。
实施例1
将1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸(85G)悬浮于水(425ml，5倍量)中，于内部温度80-85℃搅拌10分钟。在同样的温度下保温过滤后，干燥，得到目的物(84.43g)，得率92.7％。
元素分析(％)：C19H22FN3O4·3/2H2O
           C     H      N    水分
计算值    56.71    6.26    10.44    6.7
实测值    56.79    6.15    10.44    7.3
(1)使用的仪器和设备
TG/DTA                理学电气(TAS-200；控制部)、
                      TG8101D2(测定装置)
红外分光光度计        日立制作所270-30型
X射线衍射装置         理学电气2013型
单结晶X射线衍射装置   理学电气AFC5R型
Karl Fischer湿度计    京都电子工业MKA-3P型
1)热分析(TG/DTA)
本发明物质和未经热水处理的对照物的样品各用约10mg，以α-氧化铝为对照，以5℃/分钟的升温速度从室温加热至240℃，分别测定这时的重量变化和热变化，其结果，本发明物见图1，对照物见图2。
2)红外吸收谱
本发明物和未经热水处理的对照物的各样品用KBr-透射法进行测定。其结果，本发明物和对照物分别见图3和图4。
3)粉末X射线衍射
将本发明物和对照物的各样品粉碎，用玻璃试样板进行测定，其结果，本发明物和对照物分别见图5和图6。
4)单结晶X射线衍射
X射线衍射的结果，所得结晶的结构显示于图7。
1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物在通常的保存条件下保持一定量的水分，是稳定的。
将未处理物与本发明的热水处理物的热分析(TG/DTA)、红外吸收谱和粉末X射线衍射的测定数据进行比较，情况显然不同。十分明显，热水处理物与未处理物的晶型不同。
而且，从X射线衍射的结果证明了1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物在单位晶格中含有1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸8分子和水12分子。
产业上利用的可能性
本发明的1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物的崩解性和溶出性俱优，且稳定性也好，在制剂生产上是有非常用的。

Claims (2)

1.
Figure A9519698300021
所示的1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸·3/2水合物。
2.如权利要求1所述化合物的制备方法，其特征在于将1-环丙基-6-氟代-1，4-二羟基-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的水悬浮液进行加热搅拌处理。
CNB951969838A 1994-12-21 1995-12-05 稳定性优良的8-烷氧基喹诺酮羧酸水合物及其制备方法 Expired - Lifetime CN1137890C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP33556994A JP3449658B2 (ja) 1994-12-21 1994-12-21 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
JP335569/1994 1994-12-21
JP335569/94 1994-12-21

Publications (2)

Publication Number Publication Date
CN1171108A true CN1171108A (zh) 1998-01-21
CN1137890C CN1137890C (zh) 2004-02-11

Family

ID=18290056

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB951969838A Expired - Lifetime CN1137890C (zh) 1994-12-21 1995-12-05 稳定性优良的8-烷氧基喹诺酮羧酸水合物及其制备方法

Country Status (15)

Country Link
US (1) US5880283A (zh)
EP (1) EP0805156B1 (zh)
JP (1) JP3449658B2 (zh)
KR (1) KR100381644B1 (zh)
CN (1) CN1137890C (zh)
AT (1) ATE216381T1 (zh)
AU (1) AU694946B2 (zh)
CA (1) CA2208704C (zh)
DE (1) DE69526453T2 (zh)
DK (1) DK0805156T3 (zh)
ES (1) ES2173982T3 (zh)
HU (1) HU227795B1 (zh)
PT (1) PT805156E (zh)
TW (1) TW393479B (zh)
WO (1) WO1996019472A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102757419A (zh) * 2012-08-08 2012-10-31 四川百利药业有限责任公司 一种加替沙星的纯化方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
TWI287987B (en) * 2000-08-14 2007-10-11 Senju Pharma Co Cytokine inhibitor
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
JP2002363172A (ja) * 2001-06-05 2002-12-18 Showa Denko Kk ５−アルキルオキサゾリジン−２，４−ジオンの製造方法
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
AU2003230831A1 (en) * 2002-04-08 2003-10-27 Dr. Reddy's Laboratories Limited ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)
EP1503762A2 (en) * 2002-05-10 2005-02-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
US7423153B2 (en) * 2002-05-10 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of gatifloxacin
EP1645274A1 (en) * 2002-05-10 2006-04-12 Teva Pharmaceutical Industries Ltd. Process for making gatifloxacin form omega
CA2489377A1 (en) * 2002-06-14 2003-12-24 Valerie Niddam-Hildesheim Novel crystalline forms of gatifloxacin
CA2494518A1 (en) 2002-08-06 2004-02-12 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
WO2004069825A1 (en) * 2002-08-14 2004-08-19 Teva Pharmaceutical Industries Ltd. Synthesis of gatifloxacin
WO2004054583A1 (en) * 2002-12-12 2004-07-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of gatifloxacin and processes for preparation
US20050085640A1 (en) * 2003-04-02 2005-04-21 Hetero Drugs Limited Novel crystalline forms of gatifloxacin
WO2004101547A1 (en) * 2003-05-19 2004-11-25 Hetero Drugs Limited Purification methods of gatifloxacin and a novel form of gatifloxacin
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
ES2232310B1 (es) * 2003-11-13 2006-08-01 Quimica Sintetica, S.A. Formula cristalina no higroscopica de gatifloxacino.
ES2232311B1 (es) * 2003-11-13 2006-08-01 Quimica Sintetica, S.A. Forma cristalina de gatifloxacino.
US7781585B2 (en) 2004-06-04 2010-08-24 Matrix Laboratories Ltd Crystalline forms of Gatifloxacin
US20090156577A1 (en) * 2004-09-09 2009-06-18 Benjamin Davis 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US20060247255A1 (en) * 2005-05-02 2006-11-02 Patel Satishkumar A Method for preparing a stable gatifloxacin composition
US20080139574A1 (en) 2006-11-30 2008-06-12 Cadila Healthcare Limited Novel quinoline derivatives
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
US7902227B2 (en) 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
US7884099B2 (en) * 2007-11-16 2011-02-08 Cumbre Ip Ventures, L.P. Quinolone carboxylic acid-substituted rifamycin derivatives
JP2013510097A (ja) * 2009-11-03 2013-03-21 リウ、リー タンシノンｉｉａスルホン酸ナトリウム水和物、並びにその調製方法及び使用
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985747A (en) * 1974-05-24 1976-10-12 Bristol-Myers Company Crystalline sesquihydrate of 7-[D-α-amino-α-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
DE3248506A1 (de) * 1982-12-29 1984-07-05 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7(alkyl-1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
JPS62205060A (ja) * 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd ８位置換キノロンカルボン酸誘導体
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
JPS63198664A (ja) * 1986-03-31 1988-08-17 Sankyo Co Ltd キノロンカルボン酸誘導体
CA2128601C (en) * 1992-01-31 2003-07-15 Hiroyuki Nagano Quinolone carboxylic acid derivatives in crystalline hydrate form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102757419A (zh) * 2012-08-08 2012-10-31 四川百利药业有限责任公司 一种加替沙星的纯化方法

Also Published As

Publication number Publication date
HU227795B1 (en) 2012-03-28
CA2208704A1 (en) 1996-06-27
JPH08176143A (ja) 1996-07-09
US5880283A (en) 1999-03-09
TW393479B (en) 2000-06-11
AU694946B2 (en) 1998-08-06
ATE216381T1 (de) 2002-05-15
DE69526453T2 (de) 2002-12-12
DE69526453D1 (de) 2002-05-23
KR100381644B1 (ko) 2003-08-30
CN1137890C (zh) 2004-02-11
AU3994695A (en) 1996-07-10
EP0805156A4 (en) 1998-04-15
EP0805156A1 (en) 1997-11-05
EP0805156B1 (en) 2002-04-17
DK0805156T3 (da) 2002-05-06
ES2173982T3 (es) 2002-11-01
PT805156E (pt) 2002-09-30
JP3449658B2 (ja) 2003-09-22
HUT77945A (hu) 1998-12-28
CA2208704C (en) 2005-05-03
WO1996019472A1 (fr) 1996-06-27

Similar Documents

Publication Publication Date Title
CN1137890C (zh) 稳定性优良的8-烷氧基喹诺酮羧酸水合物及其制备方法
RU2066324C1 (ru) Кристаллический дигидрат азитромицина и способ его получения
US20190284308A1 (en) An improved process for the preparation of sugammadex
KR20100038081A (ko) 비정질 리팍시민 제조방법 및 이에 의해 제조된 비정질 리팍시민
US20040242556A1 (en) Novel crystalline form of cefdinir
US6586576B2 (en) Preparation method of azithromycin hydrates
WO2007010555A2 (en) Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof
JP2006219496A (ja) レボフロキサシンの精製製法
US20050137182A1 (en) Novel crystalline form of cefdinir
CN1025616C (zh) 喹啉羧酸的制备方法
JP6321135B2 (ja) ３’，５’−サイクリックジアデニル酸の包接化合物、およびその製造法
CN86102565A (zh) 硝基呋喃衍生物的制备方法及其在医疗上的应用
WO2013181251A1 (en) Crizotinib hydrochloride salt in crystalline
WO2018067805A1 (en) Solid state forms of sotagliflozin
CN111662351B (zh) 新奥克梯隆型皂苷元衍生物及制备抗耐药菌药物应用
CN1011410B (zh) 喹诺酮羧酸衍生物的制备方法
WO2014021652A1 (ko) 무수 아리피프라졸 결정 및 이의 제조방법
KR20100112672A (ko) 새로운 결정형을 갖는 7-아미노-3-비닐-세팔로스포린산염 수화물 및 이의 제조방법
CN110642792B (zh) 艾拉普林中间体的制备方法
IE57746B1 (en) Method of synthesizing esters
JPH0625100A (ja) 反強誘電性液晶化合物
US20080300258A1 (en) Anhydrous ciprofloxacin hydrochloride
WO2019169988A1 (zh) 埃格列净的晶型及其制备方法
CN1079797C (zh) 一种稠合三环化合物的二水合物结晶,制备方法及用途
CN113620982A (zh) Crisaborole溶剂化物的晶型及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040211

EXPY Termination of patent right or utility model